Lucienne Costa‐Frossard

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Comparative Diagnostic Accuracy of Ganglion Cell-Inner Plexiform and Retinal Nerve Fiber Layer Thickness Measures by Cirrus and Spectralis Optical Coherence Tomography in Relapsing-Remitting Multiple Sclerosis

J.J. González‐López, Gema Rebolleda, Marina Leal et al. · BioMed Research International · 2014 · 81 citations · Full text

Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis

Carmen Picón, Lucienne Costa‐Frossard, Raquel Alenda et al. · Clinical & Experimental Immunology · 2015 · 65 citations · Full text

High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis

Luisa María Villar, Mercedes Espiño, Lucienne Costa‐Frossard et al. · Clinica Chimica Acta · 2012 · 62 citations

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurobiology Of Disease +11

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

José Ignacio Fernández-Velasco, Jens Kühle, Enric Monreal et al. · Neurology Neuroimmunology & Neuroinflammation · 2021 · 61 citations · Full text